Skip to content

Comparison Of Effects of MRP Vs NDT For Balance and Gait in Chronic Ischemic Stroke Patients RCT

Comparison Of Effects of Motor Relearning Program (MRP) Versus Neuro Development Treatment (NDT) For Balance and Gait in Chronic Ischemic Stroke Patients: A Randomized Clinical Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05810844
Enrollment
40
Registered
2023-04-12
Start date
2023-04-01
Completion date
2023-08-31
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Brief summary

To determine the comparison between effects of Motor Relearning Program (MRP) and Neuro-Development Treatment (NDT) on balance and gait in chronic ischemic stroke patients.

Interventions

DIAGNOSTIC_TESTMotor Relearning Program (MRP)

MRP technique with a conventional physiotherapy treatment. Conventional physiotherapy treatment will help to reduce the functional impairments in chronic ischemic stroke

DIAGNOSTIC_TESTNeuro Development Treatment (NDT)

Neuro-Development Treatment NDT as well as conventional treatment. Conventional physiotherapy treatment will help to reduce the functional impairments in chronic ischemic stroke patients

Sponsors

Superior University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
45 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Chronic ischemic stroke Patients more than 6 months. (55) 2. Patient with good cognitive status minimum 20 or greater out of 30 in Mini mental state examinations.(56) 3. Age between 45-65 years.(57) 4. Patient with limb spasticity equal to 2 or less than 2 on Modified Ashworth scale.(56) 5. Both male and female patients.(58)

Exclusion criteria

1. History of neurologic disease(59, 60) 2. History of lower limb fracture.(61) 3. History of spinal cord fracture.(61) 4. Patient with skin discoloration, skin ulcers and skin allergy.(62) 5. Patients with a history of the recurrent stroke. (63) 6. Patients with any peripheral vascular disease.(60)

Design outcomes

Primary

MeasureTime frame
Effects of Motor Relearning Program Techinique, Neuro Development Treatment Techinique6 Months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026